2017 American Transplant Congress
Outcomes of 100 ABO Incompatible Kidney Transplants: A Single US Center Experience.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
IntroductionAcceptable patient and graft outcomes of ABO incompatible (ABOi) living donor kidney transplantation (LDKT) have been reported with the use of desensitization strategies. Data on…2017 American Transplant Congress
Eliminating False Positive Virtual Crossmatch Results for Lung Transplant Candidates by Using Multiple Antibody Testing Platforms.
Purpose: At present, immunologic risk for lung transplant patients is evaluated based on Virtual crossmatch (VXM) by comparing recipient's HLA antibodies detected by Single antigen…2017 American Transplant Congress
Timing of HLA Testing as a Means of Reducing Cost and Increasing Efficiency of Living Kidney Donation.
Medicine, University of Rochester Medical Center, Rochester, NY
Purpose: Creating an effective living kidney donor process can be a challenge for transplant centers. There needs to be a balance between efficiency, resources, patient…2017 American Transplant Congress
Incidence of De Novo Donor-Specific Antibodies Following Kidney Transplantation.
With a range of frequencies reported in several small studies, true incidence of de novo donor-specific human leukocyte antigen (HLA) antibodies (dnDSA) is unknown. As…2017 American Transplant Congress
Effect of Preformed Donor-Specific Antibodies in Intestine/Multivisceral Transplantation.
Aim: To analyze the effect of preformed donor-specific antibodies (DSA) in intestine/multivisceral transplantation patients.Methods: Retrospective review of preformed and de novo DSAs of all intestine/multivisceral…2017 American Transplant Congress
Outcome of Living-Donor Kidney Transplantation in Cross-Match-Positive Recipients at a Single Center.
BackgroundLiving-donor kidney transplantation in cross-match (XM)-positive patients remains high-risk and requires an optimal desensitization protocol. We started a desensitization protocol for XM-positive patients in January…2017 American Transplant Congress
Is the Time of Appearance and Resolution of De Novo HLA-DP Donor Specific Antibodies Associated with Reduced Deleterious Effect on Lung Transplant Outcomes?
Introduction: The impact of HLA-DP de novo donor specific antibodies (dDSA) to lung transplantation (LT) is poorly understood. This study analyzed the association of timely…2017 American Transplant Congress
Tacrolimus Time in Therapeutic Range Predicts Adverse Clinical Outcomes in the First Year of Kidney Transplant.
University of Colorado, Aurora, CO
Tacrolimus (TAC) has a narrow therapeutic range, with its upper bounds limited by serious toxicities while TAC minimization strategies have demonstrated immunologic risk. Monitoring the…2017 American Transplant Congress
Determinants of Severe Interstitial Fibrosis in Kidney Allografts: Major Impact of Circulating Donor-Specific Anti-HLA Antibodies.
Paris Translational Research Center for Organ Transplantation, Paris, France
Interstitial fibrosis represents a major cause of kidney allograft failure. We investigated the independent contribution of circulating donor-specific anti-HLA antibodies (DSA) in the development of…2017 American Transplant Congress
IgG Antibody Subclasses in Potential Renal Transplant Recipients with DSA, AHG-CDC CxM Negative and FxM Positive or Negative with Their Potential Donors.
Background. In kidney transplant recipients, IgG3 and IgG4 DSA have been associated with shorter time to acute AMR and with later allograft injury (glomerulopathy &…
- « Previous Page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- …
- 47
- Next Page »